MétaCan
Menu
Back to cohort
Record W1549218909

I'm Still Your Baby: Canada's Continuing Support of U.S. Linkage Regulations for Pharmaceuticals

2011· article· en· W1549218909 on OpenAlexaboutno aff
Ron A. Bouchard

Bibliographic record

VenueMarquette intellectual property law review · 2011
Typearticle
Languageen
FieldDecision Sciences
TopicResearch, Science, and Academia
Canadian institutionsnot available
Fundersnot available
KeywordsIntellectual propertyNoticePharmaceutical industryStatus quoPatentabilityBusinessStatutory lawLaw and economicsPublic economicsLawInternational tradeEconomicsPolitical sciencePatent lawMedicinePharmacology
DOInot available

Abstract

fetched live from OpenAlex

Canada's linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in under intense political pressure to balance effective patent enforcement over new and innovative drugs with the timely market entry of lower-priced generic competitors. It has been almost two decades since the regulations were enacted, and to date, there has been little objective assessment as to whether the regulations have, in fact, stimulated innovation and timely generic entry. We recently completed three empirical studies on the linkage between drug approval and drug patenting under the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations). Of particular interest was the nexus between the innovative character of new and follow-on drugs approved by Canadian regulators and the scope of intellectual property protection afforded to these drugs via operation of linkage regulations. The first study focused on the type of brand-name and generic drug approvals over an eight-year term following the coming into force of the linkage regime and leading up to the debate on progressive licensing of drug products. The second was an analysis of patenting characteristics for therapeutic products before and after the coming into force of the NOC Regulations. That study also involved a detailed analysis of patent and therapeutic classes in which multinational drug companies are focusing their attention and how these can be used to support various types of new and follow-on drug development. The third was a more nuanced analysis of the innovative nature of new and follow-on drugs approved by regulators over this time frame coupled with an investigation into how patent monopoly periods for pharmaceuticals were extended via the linkage regulations. The implications of the data for the vires of pharmaceutical linkage are discussed in light of the stated goals of government to stimulate new and innovative drug development and facilitate timely entry of generic products and, thus, to balance the goals and objectives of food and drug law with those of enabling patent legislation. The Article finishes with a brief description of the global evolution of pharmaceutical linkage and raises issues for further research into local and global systems of pharmaceutical law and policy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.017
metaresearch head score (Gemma)0.044
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.917
Threshold uncertainty score0.601

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0170.044
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.003
Science and technology studies0.0140.005
Scholarly communication0.0130.003
Open science0.0020.002
Research integrity0.0070.007
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.334
GPT teacher head0.428
Teacher spread0.093 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designTheoretical or conceptual
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueMarquette intellectual property law reviewSame topicResearch, Science, and AcademiaFrench-language works237,207